ArticleClinical ophthalmology (Auckland, N.Z.)2020
Multimodal Evaluation of Visual Function in Geographic Atrophy versus Normal Eyes.
Article in Clinical ophthalmology (Auckland, N.Z.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Geographic Atrophy Size Progression Correlates Better with Longitudinal Changes in Quantitative Contrast Sensitivity than Visual Acuity.Ophthalmology science · 2026Article
- Visual Function Assessment in Geographic Atrophy: A Review.Clinical & experimental ophthalmology · 2026Review
- [Progression assessment for geographic atrophy].Die Ophthalmologie · 2025Review
- Clinical Trial Simulation in Geographic Atrophy: Patient, Caregiver, and Trial Site Staff Perspectives.Ophthalmology and therapy · 2025Article
- Age-related macular degeneration: natural history revisited in geographic atrophy.Eye (London, England) · 2025Review
- The MOSAIC Study: A Mixed-Methods Study of the Clinical, Emotional, and Financial Burden of Geographic Atrophy Among Patients and Caregivers in the US.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Vision-related quality of life is selectively affected by comorbidities in patients with geographic atrophy.BMC ophthalmology · 2023Article
- Perspectives from clinical trials: is geographic atrophy one disease?Eye (London, England) · 2023Review
- Prediction of visual function from automatically quantified optical coherence tomography biomarkers in patients with geographic atrophy using machine learning.Scientific reports · 2022Article
- Prediction Error Stabilization and Long-Term Standard Results with a Monofocal Intraocular Lens.Vision (Basel, Switzerland) · 2022Article
- Seeing Beyond Anatomy: Quality of Life with Geographic Atrophy.Ophthalmology and therapy · 2021Article
- Humanistic and Economic Burden of Geographic Atrophy: A Systematic Literature Review.Clinical ophthalmology (Auckland, N.Z.) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo comprehensively evaluate visual function in eyes with geographic atrophy (GA) as compared to normal eyes. PATIENTS AND
methodsSixty-three eyes from 63 patients ≥50 years old were recruited for this observational study; 31 were identified as normal macular health eyes and 32 with GA. Visual function was tested with best corrected visual acuity (BCVA), low luminance visual acuity (LLVA), low luminance deficit (LLD), reading speed, macular integrity microperimetry, fixation stability, and contrast sensitivity function (CSF). Anatomic function was evaluated with spectral-domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF). Quality of life and vision were assessed with the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25).
resultsVisual function and quality of life are reduced in patients with GA. Moderate and strong correlations in the GA group were found between maximum reading speed (r = 0.787) (p˂0.01), CS spatial frequency 3 cpd (r = 0.441) (p˂0.05), CS spatial frequency 6 cpd (r = 0.524) (p˂0.01), fixation P1 (r = 0.379) (p˂0.05), macular sensitivity (r = 0.484) (p˂0.05) and atrophic area (r = -0.689) (p˂0.01), and the VFQ-25 composite score.
conclusionThe decreased visual function is reflected in a poor quality of life in patients with GA. Reading speed, contrast sensitivity, fixation, and macular sensitivity are strongly associated with vision-related quality of life. The results suggest the importance of the reading letter size in patients with GA. Microperimetry and reading speed are useful tools to better assess visual impairment in patients with GA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.